Intelligent Bio Solutions Inc. filings document a medical technology issuer commercializing rapid, non-invasive fingerprint sweat drug screening and reporting through periodic material-event disclosures. Recent 8-Ks cover operating results, preliminary revenue information, Regulation FD presentations, clinical study program updates tied to the Intelligent Fingerprinting Drug Screening System, and manufacturing disclosures for readers and lateral-flow test strips.
The filing record also includes capital-structure and governance subjects, including common stock issued through warrant exercises and an at-the-market offering agreement, restricted stock awards under the 2019 Long Term Incentive Plan and Australian Sub-Plan, and Nasdaq Capital Market bid-price compliance notices. These disclosures frame the company's product commercialization, regulatory pathway, equity compensation, share count and listing-status matters.
INTELLIGENT BIO SOLUTIONS INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 163,571 shares of Common Stock, representing 9.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power over these shares under an Investment Management Agreement.
The report is a joint Schedule 13G filing executed by Steven Boyd on 05/15/2026 and identifies Armistice Capital Master Fund Ltd. as the direct holder while the Master Fund disclaims direct beneficial ownership due to the Investment Management Agreement.
Intelligent Bio Solutions Inc. reported strong fiscal third quarter 2026 growth, with revenue of $1.06 million, up 46% year-over-year, and nine-month revenue of $3.07 million, up 39%.
Gross profit margin improved to 50.5% in Q3 and 49.3% for the nine months, about 800 basis points higher than a year earlier, driven mainly by higher-margin cartridge sales. Despite this progress, the company still posted a Q3 net loss of $2.86 million and a nine-month net loss of $8.52 million, although cash and cash equivalents increased to $6.86 million as of March 31, 2026, helped by capital raising.
Intelligent Bio Solutions Inc. reported strong revenue growth but continued losses for the quarter and nine months ended March 31, 2026. Revenue rose to $1.06 million for the quarter and $3.07 million for nine months, representing approximately 46% and 39% increases over the prior-year periods, driven by new customers and higher cartridge reorders. Gross margin improved to about 50% for the quarter and 49% for nine months as volumes and product mix shifted toward higher-margin consumables.
Despite this, the company posted a nine‑month net loss of $8.55 million and used $8.74 million of cash in operating activities. Cash and cash equivalents were $6.86 million as of March 31, 2026, with shareholders’ equity of $8.75 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months without additional financing and expects ongoing operating losses.
To support liquidity, the company raised capital through an at‑the‑market program and warrant exercises, and completed a December 2025 private placement with gross proceeds of about $10.0 million. Common shares outstanding increased to 2,391,846 as of May 12, 2026, reflecting significant equity issuance.
Intelligent Bio Solutions Inc. filed a current report highlighting two main updates. The company furnished an investor presentation made available on April 20, 2026, describing its business and operations and accessible through the Investors section of its website.
The company also reported that its total outstanding common shares were 2,176,848 as of April 20, 2026. This outstanding share count reflects issuances tied to exercised warrants and sales of common stock under a previously disclosed at-the-market offering agreement since a prior filing on March 23, 2026.
Intelligent Bio Solutions Inc. granted new restricted stock awards and reported an update on its at-the-market (ATM) offering capacity. On March 18, 2026, the CEO and CFO each received 9,150 time-vesting shares and 21,350 performance-vesting shares under the 2019 Long Term Incentive Plan, with multi-year vesting tied to clinical, FDA submission, and commercial milestones and a ten-year deadline for meeting performance goals.
Non-employee directors received an aggregate 20,000 time-vesting shares, while non-executive employees received 10,500 time-vesting and 24,500 performance-vesting shares. The company stated that total common shares outstanding were 2,001,173 as of March 23, 2026. It also filed a 2026 ATM prospectus supplement, allowing sales of additional common stock with an aggregate gross sales price of up to $3,966,316 under its existing Form S-3 shelf and ATM agreement.
Intelligent Bio Solutions, Inc. is offering up to $3,966,316 of common stock through an at-the-market program with Ladenburg Thalmann & Co. Inc., allowing sales from time to time on Nasdaq or other U.S. trading markets. The supplement states $3,966,316 remains available under the ATM Agreement.
The supplement reports a public float of $18,572,023 based on March 23, 2026 data and 1,910,702 shares held by non-affiliates, and a last sale price of $3.43 per share on March 20, 2026. Proceeds are intended for working capital and general corporate purposes. The filing discloses substantial doubt about the company’s ability to continue as a going concern, citing cash and receivable balances and the need for additional financing.
Boyages Steven Constantine reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Steven Constantine Boyages received a grant of 5,000 restricted shares of Common Stock on March 18, 2026 under the company’s 2019 Long Term Incentive Plan. These shares vest after 12 months and may be forfeited if vesting conditions are not met. Following this equity award, Boyages holds 5,031 common shares directly. All amounts are presented on a post–1-for-10 reverse stock split basis after the company’s December 15, 2025 reverse split.
Fraser Nicola Marion reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Fraser Nicola Marion received an equity award rather than conducting an open‑market trade. On March 18, 2026, the company granted him 5,000 restricted shares of Common Stock under its 2019 Long Term Incentive Plan, at no cash purchase price.
The restricted shares vest based on time after 12 months and may be forfeited if vesting conditions are not met. Following this grant, Marion holds 5,000 shares of Common Stock directly, with all amounts presented on a post‑reverse‑split basis after the company’s prior reverse stock splits.
Sakiris Spiro Kevin reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. Chief Financial Officer Kevin Sakiris received equity awards in the form of common stock. On March 18, 2026, he was granted 9,150 restricted shares that vest over 48 months and 21,350 restricted shares subject to both performance-based and time-based vesting, all under the 2019 Long Term Incentive Plan.
Following these compensation grants, Sakiris directly holds 33,981 shares of common stock and indirectly holds 1,911 shares through Anest Holdings Pty Ltd, as trustee of the S&T Sakiris Superannuation Fund. All share amounts are presented after a prior 1-for-10 reverse stock split.
Hurd Jonathan Scott reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Jonathan Scott Hurd received a grant of 5,000 restricted shares of Common Stock on March 18, 2026 under the company’s 2019 Long Term Incentive Plan. The shares vest after 12 months and can be forfeited until vested. Following this award, he holds 5,006 shares directly, with all amounts presented after a 1-for-10 reverse stock split effected on December 15, 2025.